Cancer Treatment Reviews
Volume 24, Issue 4 , Pages 249-263 , August 1998

High-dose chemotherapy with autologous stem cell support in patients with breast cancer

References 

  1. Early Breast Cancer Trialists' Collaborative Group. Systematic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. In: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;p. 1–15
  2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. In: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet. 339:1992;p. 71–85
  3. Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination. Semin Oncol. 1990;17:18–32
  4. Teicher BA, Holden SA, Cucchi CA, et al.  Combination thiotepa and cyclophosphamide in vivo and in vitro. Cancer Res. 1988;48:94–100
  5. Skipper HE, Schabel FM. Quantitative and cytokinetic studies in experimental tumor systems. In:  Holand J,  Frei E editor. Cancer Medicine. Philadelphia, PA: Lea and Febiger; 1982;p. 663–684
  6. Hryniuk WM. The importance of dose intensity in the outcome of chemotherapy. Important Adv Oncol. 1988;121–141 (review)
  7. Hryniuk WM, Levine MN, Levin L. Analysis of dose intensity for chemotherapy in early (stage II) and advanced breast cancer. NCI Monogr. 1986;87–94
  8. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281–1288
  9. Tannock IF, Boyd NF, Deboer G, et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol. 1988;6:1377–1387
  10. Wood WC, Budman DR, Korzun AH, et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl I Med. 1994;330:1253–1259
  11. Antman KS, Armitage JO, Horowitz MM, Rowlings PA. Autotransplants for breast cancer in North America. In: Proc Annu Meet Am Soc Clin Oncol. 13:1994;p. A69; (meeting abstract)
  12. Antman K, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870–1879
  13. Schmitz N, Linch DC, Dreger P, et al.  Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353–357
  14. Damiani D, Fanin R, Silvestri F, et al.  Randomized trial of autologous filgrastim-primed bone marrow transplantation versus filgrastim-mobilized peripheral blood stem cell transplantation in lymphoma patients. Blood. 1997;90:36–42
  15. Ayash LJ, Elias A, Schwartz G, et al.  Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. I Clin Oncol. 1996;14:2984–2992
  16. Shapiro CL, Hurd D, Clark P, et al.  Repetitive cycles of cyclophosphamide, thiotepa and carboplatin (CTCb) intensification with peripheral blood progenitor cells (PBPC) and filgrastim (G-CSF) in advanced breast cancer patients (pts). In: Proc Annu Meet Am Soc Clin Oncol. 13:1994;p. A67; (meeting abstract)
  17. Vahdat L, Raptis G, Fennelly D, et al.  Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res. 1995;1:1267
  18. Crown J, Kritz A, Vahdat L, et al.  Rapid administration of multiple cycles of high-dose myelosuppressive chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1993;11:1144–1149
  19. Passos-Coelho J, Ross AA, Davis JM, et al.  Bone marrow micrometastases in chemotherapy-responsive advanced breast cancer: effect ofex vivo purging with 4-hydroperoxycyclophosphamide. Cancer Res. 1994/1998;54:2366–2371
  20. Ross AA, Loudovaris M, Bender JG. Immunocytochemical analysis of tumor cells in apheresis products from chemotherapy/g-csf mobilized peripheral blood and in vitro cd34+ cells from patients with metastatic breast cancer. In: Proc Annu Meet Am Assoc Cancer Res. 35:1994/1998;p. A1147; (meeting abstract)
  21. Ross AA, Cooper BW, Lazarus HM, et al.  Different rates of detection of breast cancer cells in peripheral blood stem cell (pbsc) collections in single vs multiple specimens. In: Proc Annu Meet Am Soc Clin Oncol. 13:1994/1998;p. A60; (meeting abstract)
  22. Champlin R. Purging: elimination of malignant cells from autologous blood or marrow transplants. Curr Opin Oncol. 1996/1998;8:79–83
  23. Champlin R. Purging: the separation of normal from malignant cells for autologous transplantation. Transfusion. 1996/1998;36:910–918
  24. Shpall EJ, Lemaistre CF, Holland K, et al.  A prospective randomized trial of buffy coat versus cd34-selected autologous bone marrow support in high-risk breast cancer patients receiving high-dose chemotherapy. Blood. 1997;90:4313–4320
  25. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral blood stem cell harvesting and cd34-positive cell selection. Cancer Treat Res. 1997;77:143–157
  26. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. In: A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer. 68:1991;p. 1272–1278
  27. Gribben JG, Nadler LM. The immunological treatment of human marrow in vitro in transplantation biology. Cancer Treat Res. 1993;64:189–211
  28. Gribben JG, Neuberg D, Freedman AS, et al.  Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for b-cell lymphoma. Blood. 1993;81:3449–3457
  29. Shpall EJ, Jones RB, Bast RC, et al.  4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol. 1991;9:85–93
  30. Fields KK, Elfenbein GJ, Perkins JB, Moscinski LC. High dose versus standard dose chemotherapy for the treatment of breast cancer. In: A review of current concepts. Ann NY Acad Sci. 770:1995;p. 288–304
  31. Antman K, Ayash L, Elias A, et al.  A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102–110
  32. Singh B, Elfenbein GJ, Kronish LE, Perkins JB, Fields KK. Survival duration after relapse following high-dose therapy and autologous hematopoietic stem cell transplantation for high risk breast cancer patients. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A411; (meeting abstract)
  33. Somlo G, Doroshow JH, Forman S, et al.  High-dose chemotherapy (HDCT) and stem cell rescue (SCR) for high risk breast cancer (HRBC). In: Update and prognostic indicators of overall (OS) and relapse-free survival (RFS). Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A413; (meeting abstract)
  34. Marks LB, Rosner GL, Prosnitz LIZ, Ross M, Vredenburgh JJ, Peters WP. The impact of conventional plus high dose chemotherapy with autologous bone marrow transplantation on hematologic toxicity during subsequent local-regional radiotherapy for breast cancer. Cancer. 1994;74:2964–2971
  35. Holland HK, Dix SP, Geller RB, et al.  Minimal toxicity and mortality in high-risk breast cancer patients receiving highdose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol. 1996;14:1156–1164
  36. Hansen KS, Hansen LK, Lanier KS. High-dose chemotherapy (HDC) with Cytoxan, thiotepa and carboplatin (Stamp V) and autologous hematopoietic stem cell transplantation (AHST) in stage II, III, and IV breast cancer: a community program experience. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A365; (meeting abstract)
  37. Eder JP, Antman K, Peters W, et al.  High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol. 1986;4:1592–1597
  38. Ellis GK, Green S, Schulman S, Tranum BL, Goldberg RS, Livingston RB. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group study Cancer. 1989;64:2409–2415
  39. Kalaycioglu ME, Lichtin AE, Andresen SW, Tuason L, Bolwell BJ. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol. 1995;18:491–494
  40. Kennedy MJ, Beveridge RA, Rowley SD, Gordon GB, Abeloff MD, Davidson NE. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920–926
  41. Mulder NH, Dolsma WV, Mulder PO, et al.  Long-term results of induction- and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. Anticancer Res. 1995;15:1565–1568
  42. Myers SE, Mick R, Williams SE. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Bone Marrow Transplant. 1994;13:449–454
  43. Peters WP. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of breast cancer: yes. Important Adv Oncol. 1995;215–230
  44. Peters WP, Shpall EJ, Jones RB, et al.  High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368–1376
  45. Rowlings PA, Antman KH, Fay JW, et al.  Prognostic factors for outcome of autotransplants in women with high risk primary breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A412; (meeting abstract)
  46. Schwartzberg L, West W, Birch R, et al.  Multicenter trial of dose-escalating induction, consolidation and triple alkylator intensification in newly diagnosed metastatic breast cancer (mbc). In: Proc Annu Meet Am Soc Clin Oncol. 12:1993;p. A175; (meeting abstract)
  47. Somlo G, Doroshow JH, Forman SJ, et al.  High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or highrisk primary breast cancer. Cancer. 1994;73:125–134
  48. Somlo G, Doroshow JH, Forman SJ, et al.  High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. City of Hope Bone Marrow Oncology Team Cancer. 1994;73:1678–1685
  49. Taylor CW, List AF, Azar CA, Rifkin RM, Mosley K, Dalton WS. High dose mitoxantrone (M) thiotepa (T) and cyclophosphamide (C) plus autologous stem cell rescue (ASCR) in patients with breast cancer. Breast Cancer Treat Res. 1993;27:183; (meeting abstract)
  50. Vaughan WP, Reed EC, Edwards B, Kessinger A. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant. 1994;13:619–624
  51. Vincent MD, Powles TJ, Coombes RC, McElwain TJ. Late intensification with high-dose melphalan and autologous bone marrow support in breast cancer patients responding to conventional chemotherapy. Cancer Chemother Pharmacol. 1988;21:255–260
  52. Wallerstein R, Spitzer G, Dunphy F, et al.  A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol. 1990;8:1782–1788
  53. Williams SF, Gilewski T, Mick R, Bitran JD. High-dose consolidation therapy with autologous stem-cell rescue in stage iv breast cancer: follow-up report. J Clin Oncol. 1992;10:1743–1747
  54. Bitran J, Williams SF, Mick R, Gillewski T. High-dose consolidative chemotherapy with autologous hematopoietic progenitor support in the treatment of women with stage IV breast cancer: a five-year update. Exp Hematol. 1992;20:709; (meeting abstract)
  55. Fisher B, Anderson S, Wickerham DL, et al.  Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol. 1997;15:1858–1869
  56. Henderson IC, Berry D, Demetri GD, et al.  Improved diseasefree and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with nodepositive primary breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 390a:1998;
  57. Winer E, Berry D, Duggan D, et al.  Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342. In: Proc Annu Meet Am Soc Clin Oncol. 388a:1998;
  58. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483–2489
  59. Bezwoda WR, Dansey R, Seymour L. First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology (Huntingt). 1989;46:208–211
  60. Rahman Z, Frye D, Buzdar A, Hortobagyi GA. A retrospective analysis to evaluate the impact of selection process for highdose chemotherapy (HDCT) on the outcome of patients (pt) with metastatic breast cancer (MBC). In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A78; (meeting abstract)
  61. Peters W, Jones R, Vredenburgh J, et al.  A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Breast Cancer Res Treat. 1996;37:35
  62. Peters WP, Jones RB, Vredenburgh J, et al.  A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A149; (meeting abstract)
  63. Rahman ZU, Frye DK, Buzdar AU, et al.  Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standarddose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol. 1997;15:3171–3177
  64. Somlo G, Doroshow JH, Forman SJ, et al.  High-dose chemotherapy and stem-cell rescue in the treatment of high-risk breast cancer: prognostic indicators of progression-free and overall survival. J Clin Oncol. 1997;15:2882–2893
  65. Peters WP, Berry D, Vredenburgh JJ, et al.  Five year followup of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving greater than or equal to 10 axillary lymph nodes (Duke/CALGB 8782). In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A933; (meeting abstract)
  66. Peters WP, Ross M, Vredenburgh JJ, et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993;11:1132–1143
  67. Hortobagyi GN, Buzdar AU, Champlin RE, et al.  Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high-risk primary breast cancer-a randomized trial. In: Proc Annu Meet Am Soc Clin Oncol. 471a:1998;
  68. Rodenhuis S, Richel DJ, van der Wall E, et al.  A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. In: Proc Annu Meet Am Soc Clin Oncol. 470a:1998;
  69. Greenberg PA, Hortobagyi GN, Smith TL, et al.  Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14:2197–2205
  70. Hortobagyi GN, Smith TL, Legha SSX, et al.  Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983;1:776–786
  71. Swenerton KD, Legha SS, Smith TX, et al.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979;39:1552–1562
  72. Crump M, Goss PE, Prince M, Girouard C. Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and 10 or more positive axillary lymph nodes. J Clin Oncol. 1996;14:66–69
  73. Buzdar AU, Legha SS, Hortobagyi GN, et al.  Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981;47:2798–2802
  74. Legha SS, Buzdar AU, Smith TL, et al.  Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979;91:847–852
  75. Schwartzberg L, Birch R, Weaver C, et al.  Prognostic factors after high-dose chemotherapy (HDC) for high-risk stage II and III breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A114; (meeting abstract)
  76. Weaver CH, Schwartzberg LS, Greco FA, et al.  An intent-totreat analysis of a multi-institution phase lI trial of high-dose chemotherapy (HDC) in patients with newly diagnosed stage IV breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A989; (meeting abstract)
  77. Weaver CH, West WH, Schwartzberg LS, et al.  Induction, mobilization of peripheral blood stem cells (PBSC), high-dose chemotherapy and PBSC infusion in patients with untreated stage IV breast cancer: outcomes by intent to treat analyses. Bone Marrow Transplant. 1997;19:661–670
  78. Hu WW, Negrin RS, Stockerl-Goldstein GD, et al.  Factors associated with outcome for patients with stage IV breast cancer undergoing high-dose chemotherapy with hematopoietic cell support. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A344; (meeting abstract)
  79. Dunphy FR, Spitzer G, Fornoff JE, et al.  Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 1994;73:2157–2167
  80. Doroshow JH, Somlo G, Ahn C, et al.  Prognostic factors predicting progression-free (PFS) and overall survival (OS) in patients (pts) with responsive metastatic breast cancer (MBC) treated with high-dose chemotherapy (HDCT) and bone marrow stem cell reinfusion. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A942; (meeting abstract)
  81. Ayash LJ, Wheeler C, Fairclough D, et al.  Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol. 1995;13:2043–2049
  82. Tiersten A, Raptis G, Yao TJ, et al.  Significant alterations in pulmonary function tests (PFT) in patients undergoing high dose chemotherapy (HDC) for breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A917; (meeting abstract)
  83. Shpall EJ, Jones RB, Bearman SI, et al.  Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. J Clin Oncol. 1994;12:28–36
  84. Kennedy MJ, Vogelsang GB, Jones RJ, et al.  Phase I trial of interferon gamma to potentiate cyclosporin-induced graftversus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol. 1994;12:249–257
  85. Cluitmans FH, Esendam BH, Veenhof WF, Landegent JE, Willemze RX, Falkenburg JH. The role of cytokines and hematopoietic growth factors in the autocrine/paracrine regulation of inducible hematopoiesis. Ann Hematol. 1997;75:27–31
  86. Bitran JD, Samuels B, Trujillo Y, Klein L, Schroeder L, Martinec J. Her2/neu overexpression is associated with treatment failure in women with high-risk stage II and stage Illa breast cancer (greater than 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res. 1996;2:1509–1513
  87. Gianni L, Capri G, Mezzelani A, et al.  HER-2/neu (HER2) amplification and response to doxorubicin/paclitaxel (AT) in women with metastatic breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A491; (meeting abstract)
  88. Baselga J, Seidman AD, Rosen PP, Norton L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt). 1997;11:43–48
  89. Seidman AD, Baselga Yao TJ, Gilewski T, Rosen PP, Norton L. HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A80; (meeting abstract)
  90. Tripathy D, Colbern GT, Kim D, Benz CC, Henderson IC, Smith HS. Enhanced doxorubicin dose responsiveness in vivo due to HER-2/neu overexpression. Breast Cancer Res Treat. 1994;32: (meeting abstract)
  91. Muss HB, Thor AD, Berry DA, et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260–1266
  92. Muss H, Thor A, Kute T, et al.  erbB-2 (c-erbB-27; HER-2/neu) and S-phase fraction (SPF) predict response to adjuvant chemotherapy in patients (pts) with node positive (N+) breast cancer (BC): cancer and acute leukemia group B (CALGB) trial 8869. In: Proc Annu Meet Am Soc Clin Oncol. 12:1993;p. A88; (meeting abstract)
  93. Wallerstein R, Spitzer G, Huan S, et al.  Two different courses of high-dose chemotherapy with autologous marrow rescue (‘tandem transplant’) as intensification after conventional chemotherapy for metastatic breast cancer. In: Proc Annu Meet Am Soc Clin Oncol. 10:1991;p. A149; (meeting abstract)
  94. Peters WP, Ross M, Vredenburgh JJ, et al.  The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol. 1994;21:25–31
  95. Ross M, Dukelow K, Gilbert C, et al.  Outpatient bone marrow transplantation: two year update. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A930; (meeting abstract)
  96. Peters WP. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Hematologic Malignancies. 1997; New Strategies and: (meeting abstract)
  97. Peters WP. Advances in the supportive care of patientsreceiving high-dose chemotherapy and autologous bone marrow transplantation for breast cancer. In: Supportive Care in Cancer, 4th International Symposium. 24–27 February 1993; (meeting abstract)
  98. Rahman Z, Champlin R, Rondon G, et al.  Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer. Semin Oncol. 1997;24:S17-77–S17-80
  99. Spitzer TR, Cirenza E, McAfee S, et al.  Phase I-II trial of highdose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant. 1995;15:537–542
  100. Spitzer G, Dunphy FR, Petruska PJ, Velasquez WS, Adkins DR. Tandem transplants in solid tumors: marrow versus peripheral stem cell transplant: peripheral blood cells as now practiced are not the whole answer. I Hematother. 1993;2:363–365
  101. Spitzer TR, Cirenza E, Foelber R, et al.  High-dose cyclophosphamide (CY), carboplatin (CARBO) and autologous bone marrow (ABMT) or peripheral blood stem cell transplantation (PBSCT) for breast cancer (BC). In: Proc Annu Meet Am Soc Clin Oncol. 12:1993;p. A198; (meeting abstract)
  102. Crown J, Vahdat L, Raptis G, et al.  Rapidly cycled courses of high-dose (HD) chemotherapy (C) supported by filgrastim (G) and peripheral blood progenitors (PBP) in patients (pts) with metastatic breast cancer (MBC). In: Proc Annu Meet Am Soc Clin Oncol. 13:1994;p. A243; (meeting abstract)
  103. Gajewski J, Rondon G, Mirza N, et al.  Preliminary results of a randomized trial comparing intensive chemotherapy with growth factor (GF) for peripheral blood progenitor cell (PBPC) mobilization to GF alone for hematopoieitic rescue after high-dose chemotherapy. In: Proc Annu Meet Am Soc Clin Oncol. 17:1998;p. 80a; (abstract)
  104. Riccio L, Hudis C, Seidman A, et al.  Long-term distant diseasefree survival (DFS) from two pilot studies of dose-dense sequential adjuvant chemotherapy (CRX) in women (pts) with resected breast cancer (BC) and more than 3 positive lymph nodes (+LN). In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A507; (meeting abstract)
  105. Hudis C, Seidman A, Raptis G, et al.  Sequential (Seq) dosedense (DD) doxorubicin (A)/paclitaxel (T)/cyclophosphamide (C) is less toxic than A/concurrent (Con) T+C as adjuvant therapy in resected node positive (+) breast cancer (NPBC). In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A143; (meeting abstract)
  106. Fennelly D, Shapiro F, Schneider J, et al.  A novel approach to delivery of dose-dense chemotherapy (C) in patients (pts) with advanced ovarian cancer (AOC): a phase I trial. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A921; (meeting abstract)
  107. Stiff PJ, Bayer R, Tan S, et al.  High-dose chemotherapy combined with escalating doses of cyclosporin A and an autologous bone marrow transplant for the treatment of drugresistant solid tumors: a phase I clinical trail. Clin Cancer Res. 1995;1:1495–1502
  108. Ruvolo P, Bright E, Kennedy MJ, et al.  Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the V beta T -cell receptor repertoire. Transplant Proc. 1995;27:1363–1365
  109. Kennedy MJ, Hess AD, Passos-Coelho JL, et al.  Peripheral blood progenitor cell (PBPC) infusions do not inhibit the induction of autologous graft vs host disease (AGVHD) by cyclosporine A (CSA) following high-dose chemotherapy. In: Proc Annu Meet Am Soc Clin Oncol. 14:1995;p. A915; (meeting abstract)
  110. Kennedy MJ, Vogelsang GB, Beveridge RA, et al.  Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol. 1993;11:478–484
  111. Stiff P, Bayer R, Sosman J, Peace D, Rad N, Kinch L. Highdose chemotherapy with marrow rescue and cyclosporin A: a combined modality approach to overcome drug resistance in solid tumors. In: Proc Annu Meet Am Soc Clin Oncol. 12:1993;p. A327; (meeting abstract)
  112. Rahman Z, Kavanagh J, Giles R, et al.  Paclitaxel immediately following autologous bone marrow transplantation further reduces residual disease in patients with metastatic breast cancer (MBC). In: Proc Annu Meet Am Assoc Cancer Res. 38:1997;p. A165; (meeting abstract)
  113. Ueno NT, Rondon G, Mirza NQ, et al.  Allogeneic peripheralblood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986–993
  114. Garcia-Sanchez F, Pizzorno G, Cooperberg M, Krause DS, Crystal R, Deisseroth AB. Effective bone marrow purging using an adenovirus vector containing the prodrug activation unit cytosine deaminase. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997/1998;p. A320; meeting abstract
  115. Chung I, Crystal RG, Schwartz P, et al.  Cytotoxicity of cytosine deaminase (cd) adenoviral vectors (av) with a promoter (Iplastin) for epithelial cancer cells. In: Effective bone marrow purging using an adenovirus vector containing the prodrug activation unit cytosine deaminase. Proc Annu Meet Am Soc Clin Oncol. 16:1997/1998;p. A320; (meeting abstract)
  116. Chung I, Crystal RG, Schwartz P, Pizzorno G, Deisseroth AB. Chemosensitization of human ovarian carcinoma by recombinant adenoviral vector containing tumor-specific cytosine deaminase transcription unit. In: Proc Annu Meet Am Assoc Cancer Res. 38:1997/1998;p. A2549; (meeting abstract)
  117. O'Shaughnessy JA, Cowan KH, Nienhuis AW, et al.  Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther. 1994;5:891–911
  118. Hanania EG, Giles RE, Claxton D, et al.  Multiple drug resistance (MDR-1) genetic chemoprotection autologous transplants of retroviral vector mediated MDR-1 stromal transduced CD34 selected cells generate post-transplant bone marrow positive for viral MDR-1 sequences. In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A583; (meeting abstract)
  119. Douer D, Levine A, Anderson WF, et al.  High-dose chemotherapy and autologous bone marrow plus peripheral blood stem cell transplantation for patients with lymphoma or metastatic breast cancer: use of marker genes to investigate hematopoietic reconstitution in adults. Hum Gene Ther. 1996;7:669–684
  120. Dunbar CE, Bodine DM, Sorrentino B, et al.  Gene transfer into hematopoietic cells. In: Implications for cancer therapy. Ann NY Acad Sci. 716:1994;p. 216–224 discussion Dunbar CE, Bodine DM, Sorrentino B, et al.  Gene transfer into hematopoietic cells. In: Implications for cancer therapy. Ann NY Acad Sci. 716:1994;p. 224–227 discussion
  121. Cowan KH, O'Shaughnessy J, Schneider E, et al.  Transfer of drug resistance genes into human hematopoietic cells. (Meeting abstract) In: SBT93: Society for Biological Therapy, 8th Annual Scientific Meeting: Biological Therapy of Cancer - VIII. 10–14 November 1993;
  122. Hanania EG, Giles RE, Claxton D, et al.  Post-transplant frequency of genetically modified cells using retroviralmediated multiple drug resistance (MDR-1) stromal transduction protocol in breast and ovarian cancers. In: Proc Annu Meet Am Assoc Cancer Res. 37:1996;p. A2363; (meeting abstract)
  123. Hanania EG, Fu S, Roninson I, Zu Z, Deisseroth AB. Resistance to taxol chemotherapy produced in mouse marrow cells by safety-modified retroviruses containing a human MDR-1 transcription unit. Gene Ther. 1995;2:279–284
  124. Hanania EG, Fu S, Zu Z, et al.  Chemotherapy resistance to taxol in clonogenic progenitor cells following transduction of CD34 selected marrow and peripheral blood cells with a retrovirus that contains the MDR-1 chemotherapy resistance gene. Gene Ther. 1995;2:285–294
  125. Hanania EG, Deisseroth AB. Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther. 1994;1:21–25
  126. Deisseroth AB, Zu Z, Claxton D, et al.  Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood. 1994;83:3068–3076
  127. Bachier C, Giles RE, Ellerson D, et al.  CD34 + selection and retroviral hematopoietic gene marking to determine the role of bone marrow and peripheral blood grafts on relapse in patients with follicular non-Hodgkin's lymphoma (FNHL). In: Proc Annu Meet Am Soc Clin Oncol. 15:1996;p. A574; (meeting abstract)
  128. Bolotin E, Smogorzewska M, Smith S, Widmer M, Weinberg K. Enhancement of thymopoiesis after bone marrow transplant by in vivo interleukin-7. Blood. 1996;88:1887–1894
  129. Serrano F, Varas F, Bernad A, Bueren JA. Accelerated and long-term hematopoietic engraftment in mice transplanted with ex vivo expanded bone marrow. Bone Marrow Transplant. 1994;14:855–862
  130. Leigh BR, Webb S, Hancock SL, Knox SJ. Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice. Stem Cells. 1994;12:430–435
  131. de Revel T, Appelbaum FR, Storb R, et al.  Effects of granulocyte colony-stimulating factor and stem cell factor, alone and in combination, on the mobilization of peripheral blood cells that engraft lethally irradiated dogs. Blood. 1994;83:3795–3799
  132. Champlin RE, Mehra R, Kaye JA, et al.  Recombinant human interleukin eleven (rhIL-11) following autologous BMT for breast cancer. Blood. 1994;84:395a; (meeting abstract)
  133. Champlin R, Mehra R, Kaye J, et al.  Phase I study of recombinant human interleukin-11 following autologous BMT in patients with breast cancer Proc. Annu Meet Am Soc Clin Oncol. 1994;13:A201; (meeting abstract)
  134. Donato M, Korbling M, Gajewski J, Mehra R, Champlin R. Peripheral blood stem cell (PBSC) mobilization with chemotherapy and G-CSF versus G-CSF alone, with or without IL 3. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A322; (meeting abstract)
  135. Champlin R, Korbling M, Donato M, et al.  Recombinant human thrombopoietin (rhTPO) for mobilization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer: preliminary results of a phase I trial. In: Proc Annu Meet Am Soc Clin Oncol. 16:1997;p. A352; (meeting abstract)
  136. Shapiro F, Yao TJ, Raptis G, Reich L, Norton L, Moore MA. Optimization of conditions for ex vivo expansion of CD34 +cells from patients with stage IV breast cancer. Blood. 1994;84:3567–3574
  137. Moore MA, Schneider JG, Shapiro F, Bengala C. Ex vivo expansion of CD34 + hematopoietic progenitors. Prog Clin Biol Res. 1994;389:217–228
  138. Purdy MH. Positive selection and ex vivo expansion of hematopoietic progenitors as autografts for high-dose chemotherapy, potential importance in patients with bone metastases. Can J Oncol. 1995;5(Suppl. 1):63–68
  139. Silva MR, Parreira A, Ascensao JL. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion. Exp Hematol. 1995;23:1676–1681
  140. Williams SF, Lee WJ, Bender JG, et al.  Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood. 1996;87:1687–1691
  141. Vogel W, Behringer D, Scheding S, Kanz L, Brugger W. Ex vivo expansion of CD34+ peripheral blood progenitor cells: implications for the expansion of contaminating epithelial tumor cells. Blood. 1996;88:2707–2713
  142. To LB, Haylock DN, Simmons PJ, Juttner CA. Ex vivo expansion of peripheral blood CD34+ cells and their maturation to functional end cells: an adjunct to hemopoietic stem cell transplantation. Exp Hematol. 1992;20:753; (meeting abstract)
  143. Gehling UM, Ryder JW, Hogan CJ, et al.  Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34 + progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. Exp Hematol. 1997;25:1125–1139
  144. Holyoake TL, Freshney MG, McNair L, et al.  Ex vivo expansion with stem cell factor and interleukin-11 augments both shortterm recovery post-transplant and the ability to serially transplant marrow. Blood. 1996;87:4589–4595
  145. Bernad A, Varas F, Gallego JM, Almendral JM, Bueren JA. Ex vivo expansion and selection of retrovirally transduced bone marrow: an efficient methodology for gene-transfer to murine lympho-haemopoietic stem cells. Br J Haematol. 1994;87:6–17

PII: S0305-7372(98)90060-3

Cancer Treatment Reviews
Volume 24, Issue 4 , Pages 249-263 , August 1998

Article Tools